3SBio(OTC) TRSBF

Current Price$2.12

Market Cap$5.38B

Since IPO (2018)-11%

5 Year+140%

1 Year-22%

1 Month-16%

3SBio last closing stock price
Metric	Price	Date
Last close	USD 2.12	2026-06-26

3SBio stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-2.27%	USD 2.17	2026-06-12
1 month	-15.69%	USD 2.51	2026-05-27
3 month	-17.62%	USD 2.57	2026-03-26
Year to date	-39.61%	USD 3.51	2025-12-26
1 year	-22.33%	USD 2.73	2025-06-26
3 year	+187.47%	USD 0.74	2023-04-18
5 year	+139.94%	USD 0.88	2021-05-24
Since inception	-11.16%	USD 2.42	2018-06-26

3SBio Financials at a Glance

Market Cap

$5.38B

Revenue (TTM)

CN¥26.58B

Net Income (TTM)

CN¥10.45B

EPS (TTM)

$0.48

P/E Ratio

4.38

Dividend

$0.00

Beta (Volatility)

-0.08 (Low)

Dividend

$0.00

Beta (Volatility)

-0.08 (Low)

Price

$2.12

Volume

127

Open

$2.12

Price

$2.12

Volume

127

Open

$2.12

Previous Close

$2.12

Daily Range

$2.12 - $2.12

52-Week Range

$2.00 - $4.74

Estimated Earnings Date

Aug 26, 2026

Dividend

$0.00

Beta (Volatility)

-0.08 (Low)

Price

$2.12

Volume

127

Open

$2.12

Previous Close

$2.12

Daily Range

$2.12 - $2.12

52-Week Range

$2.00 - $4.74

Estimated Earnings Date

Aug 26, 2026

TRSBF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About 3SBio

3SBio Inc. is a China-based biopharmaceutical company engaged in the entire value chain from research and development to manufacturing, marketing, and sales of innovative products. The company offers a diverse portfolio of treatments for various therapeutic needs, including blood disorders, autoimmune diseases, and oncology.

Products and Services

TPIAO for chemotherapy-induced thrombocytopenia
YISAIPU, a tumor necrosis factor inhibitor for autoimmune diseases
Cipterbin for HER2-positive metastatic breast cancer

Growth Outlook

Revenue increased to CNY 13.12 billion in Q4 2025
Net income reached CNY 7.01 billion in Q4 2025
Strong operating income margin of 69.66% in Q4 2025

Financial Highlights

Trailing twelve months (TTM) revenue of CNY 43.12 billion
Net profit margin of 47.93% TTM
Current ratio of 5.13, indicating strong liquidity

3SBio Inc. has established itself as a key player in the biopharmaceutical sector, with a comprehensive range of products addressing critical health issues. The company's recent financial performance demonstrates robust growth, particularly in revenue and net income, reflecting its effective operational strategies. The strong liquidity position, as indicated by the current ratio, further supports the company's ability to navigate market challenges and invest in future growth opportunities. With a focus on innovation and strategic partnerships, 3SBio is well-positioned to capitalize on the expanding biopharmaceutical market in China and beyond.

AI Generated • Jul 25, 2026

Industry

Biotechnology

Sector

Health Care

Employees

6,109

CEO

Jing Lou, PhD, EMBA

Website

www.3sbio.com

Headquarters

Shenyang, LI 110027, CN

TRSBF Financials

Key Financial Metrics (TTM)

Gross Margin

92.38%

Operating Margin

59.59%

Net Income Margin

47.93%

Return on Equity

38.96%

Return on Capital

34.47%

Return on Assets

23.39%

Earnings Yield

22.83%

Dividend Yield

0.00%

Payout Ratio

6.37%

Stock Overview

Market Cap

$5.38B

Shares Outstanding

2.50B

Volume

127

Avg. Volume

2.79K

Financials (TTM)

Gross Profit

CN¥23.97B

Operating Income

CN¥13.14B

EBITDA

CN¥14.17B

Operating Cash Flow

CN¥12.07B

Capital Expenditure

-CN¥1.30B

Free Cash Flow

CN¥10.77B

Cash & ST Invst.

CN¥19.73B

Total Debt

CN¥2.62B

3SBio Performance Analysis

3SBio annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	CNY 1,019,605,978	3.0%
2023	2023-12-31	CNY 1,103,162,519	8.2%
2024	2024-12-31	CNY 1,265,556,326	14.7%
2025	2025-12-31	CNY 2,461,692,544	94.5%

3SBio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2024-06-30	8.9%
Q4	2024-12-31	7.5%
Q2	2025-06-30	-7.7%
Q4	2025-12-31	201.2%

3SBio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	CNY 0.11	15.2%
2023	2023-12-31	CNY 0.09	-20.2%
2024	2024-12-31	CNY 0.12	33.7%
2025	2025-12-31	CNY 0.48	305.2%

3SBio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2024-06-30	95.7%
Q4	2024-12-31	-11.1%
Q2	2025-06-30	40.0%
Q4	2025-12-31	412.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

CN¥13.12B

+225.4%

Gross Profit

CN¥12.42B

+261.1%

Gross Margin

94.69%

N/A

Market Cap

$5.38B

N/A

Market Cap/Employee

$880.11K

N/A

Employees

6,109

N/A

Net Income

CN¥7.01B

+1132.0%

EBITDA

CN¥9.43B

+1126.8%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Total Cash

CN¥19.73B

+229.3%

Total Debt

CN¥2.62B

-45.9%

Accounts Receivable

CN¥1.08B

-1.2%

Inventory

CN¥1.05B

+34.8%

Long Term Debt

CN¥768.54M

-71.7%

Short Term Debt

CN¥1.85B

-12.8%

Return on Assets

23.39%

N/A

Return on Invested Capital

33.11%

N/A

Free Cash Flow

CN¥8.42B

+1310.7%

Operating Cash Flow

CN¥8.74B

+873.1%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

SSMXYSysmex Corporation

SSMXYSysmex Corporation$9.29+1.53%

SHTDYSinopharm Group Co. Ltd.

SHTDYSinopharm Group Co. Ltd.$10.73+0.07%

REGMFRemeGen Co., Ltd.

REGMFRemeGen Co., Ltd.$12.05+0.00%

SKHCFSonic Healthcare Limited

SKHCFSonic Healthcare Limited$13.80+0.00%

KYKOFKyowa Kirin Co., Ltd.

KYKOFKyowa Kirin Co., Ltd.$14.43+0.00%

WILYYDemant A/S

WILYYDemant A/S$20.66+0.00%

WILLFDemant A/S

WILLFDemant A/S$41.51+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

INTCIntel

INTCIntel$92.32-0.08%

NOKNokia

NOKNokia$9.10-0.06%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.42-0.04%

ONDSOndas

ONDSOndas$7.80-0.02%

SOFISoFi Technologies

SOFISoFi Technologies$16.46-0.01%

NUNu Holdings

NUNu Holdings$14.09-0.01%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.48+0.07%

Questions About TRSBF

What is the current price of 3SBio?

3SBio is trading at $2.12 per share.

What is the 52-week range for 3SBio?

Over the past 52 weeks, 3SBio has traded between $2.00 and $4.74.

How much debt does 3SBio have?

As of the most recent reporting period, 3SBio reported total debt of CN¥374.61M.

How much cash does 3SBio have on hand?

3SBio reported CN¥1.76B in cash and cash equivalents in its most recent financial results.

What is 3SBio’s dividend yield?

3SBio does not currently have a dividend yield.

3SBio(OTC) TRSBF

3SBio Financials at a Glance

TRSBF News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About 3SBio

TRSBF Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

3SBio Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About TRSBF

What is the current price of 3SBio?

What is the 52-week range for 3SBio?

How much debt does 3SBio have?

How much cash does 3SBio have on hand?

What is 3SBio’s dividend yield?

Premium Investing Services